Combinatory lung tumor inhibition by myo-inositol and iloprost/rapamycin: Association with immunomodulation

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Although both preclinical and clinical studies have suggested that myo-inositol (MI) may be a safe and effective lung cancer chemopreventive agent, its efficacy is moderate. To test whether the chemopreventive agents iloprost (IL) or rapamycin enhance the lung tumor inhibitory effects of MI, A/J mice were treated with the tobacco smoke carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and, beginning one week after the end of NNK treatment, given MI, IL, rapamycin, MI+IL or MI+rapamycin for 17 weeks. Analyses of the number and size of tumors on the surface of the lung have indicated that MI, IL, rapamycin, MI+IL and MI+rapamycin reduced the multiplicity of NNK-induced lung tumors by 41, 34, 46, 79 and 67%, respectively, and larger tumors (lung tumors with a diameter of 1-2 or >2 mm) were absent in the MI+IL and MI+rapamycin groups. These results clearly indicated that MI+IL and MI+rapamycin are more effective than MI alone in inhibiting the formation and growth of lung tumors. Assessment of the immunomodulatory effects of the drugs showed that whereas MI+rapamycin and MI+IL increased the infiltration of lung tumors by CD4+ and CD8+ T cells, MI+rapamycin reduced the expression of the immune checkpoint protein programmed-death ligand-1 (PD-L1). Moreover, all treatments, except IL, increased apoptosis, whereas cell proliferation was markedly suppressed in all treated groups. In summary, these results suggest that IL and rapamycin could enhance the efficacy of MI in lung cancer chemoprevention trials.

Original languageEnglish (US)
Pages (from-to)547-556
Number of pages10
JournalCarcinogenesis
Volume43
Issue number6
DOIs
StatePublished - Jun 1 2022

Bibliographical note

Publisher Copyright:
© 2022 The Author(s) 2022.

PubMed: MeSH publication types

  • Journal Article

Fingerprint

Dive into the research topics of 'Combinatory lung tumor inhibition by myo-inositol and iloprost/rapamycin: Association with immunomodulation'. Together they form a unique fingerprint.

Cite this